Performance

Recent News

United Therapeutics Corp. shares surged 8.7% premarket on Friday after a news report suggested that major pharmaceutical companies were weighing a bid for it. The Evening Standard report said that Gilead Sciences Inc. is considered the frontrunner, while GlaxoSmithKline PLC and Novartis AG are also possible contenders. Glaxo and United Therapeutics declined to comment to the Evening Standard. United Therapeutic, which was founded by Martine Rothblatt, a co-founder of Sirius XM , currently has five products on the market, four of which treat pulmonary arterial hypertension; the fifth is intended for pediatric cancer patients. United Therapeutics shares have dropped 11.5% year-to-date, compared with a 10.4% rise in the S&P 500 .

GlaxoSmithKline PLC has axed more than 30 research programs to focus on four key areas, in a push by new Chief Executive Emma Walmsley to sharpen the company's research and development operations. The move--which will focus Glaxo's research efforts on respiratory diseases, HIV and other infectious diseases, cancer and immuno-inflammatory conditions--came as the company posted a net loss in the second quarter, in part due to higher spending on research and development.

GlaxoSmithKline PLC reports its second-quarter earnings Wednesday at 1100 BST. Here's what to expect. EARNINGS: Analysts surveyed by FactSet expect Glaxo to post net income of GBP1.14 billion in the three months to June 30. That compares with a GBP435 million loss in the year-earlier period, when the company took a GBP1.8 billion write-down after a sharp decline in the value of the pound following the U.K.'s Brexit vote increased the value of its liabilities.

LONDON-- GlaxoSmithKline PLC (GSK.LN) Friday said it received U.S. Food and Drug Administration approval for a new self-injectable form of Benlysta, a treatment for the immune system disease systemic lupus erythematosus.

LONDON--Drug and healthcare products giant GlaxoSmithKline PLC (GSK.LN) said Wednesday it plans to sell its Horlicks drinks brand in the U.K. and cut around 320 jobs in the country. Glaxo said it will seek to sell the Horlicks brand in the U.K. and close the site in Slough, England where the malted drink is made.

GlaxoSmithKline axed more than 30 drug-research projects to focus on four key disease areas, in a push by new Chief Executive Emma Walmsley to sharpen the company’s research-and-development operations.

A senior executive of Australian casino operator Crown Resorts drew a 10-month prison sentence in China after he and 18 other current and former Crown employees pleaded guilty to gambling crimes; 16 were sentenced to prison.

Recent News

Mylan (MYL) shares rose Thursday after it announced a $465 million settlement with the Justice Department over its EpiPen classification under Medicaid, and on an analyst's suggestion it could rebound from a generics downtrend. In afternoon trading on the stock market today, Mylan lifted 0.6%, near 30.70, for its third consecutive day in the black. Earlier in the month, Mylan followed in the footsteps of Teva Pharmaceutical (TEVA) with

Diabetes and Cardiovascular is one of Sanofi&#8217;s (SNY) most important business units, contributing over 20% of its pharmaceutical revenue. The franchise reported 10.7% revenue growth to 1.8 billion euros in&#8230;

Biotech stocks were on the move early Friday as GlaxoSmithKline (GSK) backed out of a deal with Ionis Pharmaceuticals (IONS), and Galapagos (GLPG) announced promising data on a lung-disease treatment. [ibd-display-video id=2078141 width=50 float=left autostart=true]In early trading on the stock market today, IBD's 444-company Biotech industry group rose 1.1%. Ionis fell 1%, near 45.15, as Glaxo was flat near 39. Galapagos popped 3.7%, near 84,

Gilead Sciences (GILD) "might end up doing nothing in oncology" if the right takeover deal doesn't present itself, Chief Executive John Milligan reportedly told an analyst Wednesday. [ibd-display-video id=2077867 width=50 float=left autostart=true]The third-largest biotech by market cap, Gilead has struggled with declining sales of hepatitis C drugs for several quarters. In the first quarter, Gilead hinted that it could be looking to buy an

GlaxoSmithKline PLC ADR

'GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products. It operates through the following segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines business produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare business markets a range of consumer health products based on scientific innovation. The company was founded on December 6, 1999 and is headquartered in Brentford, United Kingdom.
(See Full Profile)

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time.
Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.

Trending Tickers

Stocks

Columns

Authors

Topics

Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.